Thus, M-DCsTNF combined with an IAP antagonist can be used to treat advanced stage breast cancer and other solid cancers because an IAP antagonist enables TNFα to rapidly induce apoptosis in a broad range of cancers [52–54]. This evidence concerns the gene TNF and breast carcinoma.